At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,252 enrolled
Drug / intervention
Erlotinib +1 moredrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors
In Brief
A Phase 3 clinical trial evaluating Erlotinib and Placebo for Non-small Cell Lung Cancer. Completed, enrolled 1,252 participants across 295 sites in 19 countries.
Detailed Summary
This is a study to evaluate the effectiveness of erlotinib compared with a placebo sugar pill following complete surgical removal of the tumor with or without chemotherapy after surgery in Stage IB-IIIA NSCLC patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesArgentina, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Italy, Poland, Romania, Russia, South Korea, Spain, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedSep 2006
Primary CompletionApr 2013
Study CompletionJun 2014
TodayJul 2026
First PostedSep 8, 2006
Enrollment StartSep 1, 2006
Primary CompletionApr 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 19.8 years ago
Interventions
Erlotinibdrug
150 mg tablet
Placebodrug
Placebo tablet